THE HUMAN IMMUNE SYSTEM
TRANSFUSION
|
Question
[CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]
|
|
|
the proteasome
|
|
|
the cereblon
|
|
|
the CD138
|
|
|
le B-cell maturation antigen
|
Detailed explanation-1: -New treatments target BCMA protein on myeloma cells Several newer treatments for multiple myeloma-including two recently approved CAR T-cell therapies (one in 2021 and one in 2022), teclistamab, and more than half a dozen similar drugs still in development-target a protein called BCMA.
Detailed explanation-2: -B cell maturation antigen (BCMA) targeted immunotherapy can treat multiple myeloma. This therapy targets cancer cells to slow or stop their growth and prevent cells from growing out of control. BCMA-targeted treatment attack a specific antigen that is heavily present in myeloma cells.
Detailed explanation-3: -Targeted therapy for multiple myeloma includes: Proteasome inhibitors. Bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro) are classified as proteasome inhibitors. They target specific enzymes called proteasomes that digest proteins in the cells.